News
Investor's Business Daily on MSN4d
The Hits Keep Coming For Sarepta. Why Its Latest Setback Creates A 'Dangerous Precedent.'Sarepta stock plunged again Thursday on a report the FDA will require additional clinical testing to validate the safety ...
Sarepta Therapeutics is laying off 500 staffers, or 36% of its workforce, as part of a strategic restructuring aiming to save $400 million annually. | Sarepta Therapeutics has laid off 500 staffers, ...
Solid Bio’s gene therapy candidate, SGT-003, was designed to improve both safety and efficacy. Using a lower dose, this therapy is able to achieve greater levels of microdystrophin expression.
Sarepta Therapeutics said Sunday that it was halting shipments of its Duchenne muscular dystrophy gene therapy for patients who can no longer walk, following the death of a second person who ...
Pharma Sarepta reports 2nd death after DMD gene therapy Elevidys, stops dosing in half of patients By Angus Liu Jun 16, 2025 10:58am ...
Sarepta disclosed the first patient death — a 16-year-old boy — in March. Both occurred from acute liver failure, a side effect that has been seen with other gene therapies.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback